The Cooper Companies

CooperCompanies has two businesses. CooperVision makes soft contact lenses, including toric and multifocal lenses, and sells them around the world. CooperSurgical sells fertility products and services and office and surgical products for women's health. Revenue was $1.066 billion in Q3 fiscal 2026, which ended on July 31, 2026: $717.0 million from CooperVision and $349.2 million from CooperSurgical.

Its fiscal year ends on October 31. Al White stepped down as President and CEO on October 27, 2026. Walt Rosebrough, the Executive Chair, oversees daily operations until the board appoints a new CEO.

The market prices CooperCompanies for slow contact lens growth. CooperVision revenue was flat in Q3 fiscal 2026 because the company reduced U.S. channel inventory, and it expects CooperVision organic growth of minus 2% to 0% in Q4. In September 2026, the board ended a strategic review and kept CooperSurgical, because the offers it received were not in the interest of shareholders. The board said that a new competitor in non-hormonal IUDs and a fertility litigation settlement affected the value.

On October 27, 2026, CEO Al White stepped down, and the new Executive Chair, Walt Rosebrough, said that recent performance did not meet the board's expectations. A search for a permanent CEO is underway, and three directors will leave the board in 2027. For the gap to close, three things must be true. CooperVision must return to organic growth in fiscal 2027 after the inventory reduction, helped by new products and a larger sales force.

Fertility revenue must keep growing, as in Q3 when it grew 5% organically. Free cash flow must meet the target of more than $2.2 billion for fiscal 2026 to 2028 and fund buybacks under the $3 billion program. The Q4 fiscal 2026 report and the fiscal 2027 guidance on December 3, 2026, are the next test. If these checks pass, the gap can close over the next four to six quarters.

The main reason it may not close is slower growth in contact lenses, where competition is strong.

1. Dec 3, 2026Pending

   Q4 fiscal 2026 earnings and fiscal 2027 guidanceQ4 results within guidance and fiscal 2027 guidance for CooperVision organic growth pass; another guidance cut or no return to growth fail.
2. Mar 2027 · est.Pending

   Q1 fiscal 2027: CooperVision growthPositive CooperVision organic growth after the inventory reduction pass; flat or falling CooperVision revenue fails.

Every passed and failed checkpoint across all picks

• October 27, 2026Al White stepped down as President and CEO and left the board. Walt Rosebrough, an independent director, became Executive Chair and oversees daily operations until a permanent CEO is appointed, and the board started a CEO search. Shlomi Nachman, a former Johnson & Johnson executive, joins the board on December 8, 2026, and three directors will not stand for reelection in 2027. The company reaffirmed its fiscal 2026 guidance.
• September 23, 2026CooperVision opened The Vision Centre, its new global research and development center, as part of a faster program of new product introductions.
• September 9, 2026CooperCompanies reported Q3 fiscal 2026 results. Revenue rose 1% to $1.066 billion, and non-GAAP EPS rose 4% to $1.15. CooperVision revenue was flat because of a U.S. channel inventory reduction. Free cash flow rose 66% to $273.0 million, and a $307.2 million tax benefit followed the end of a U.K. tax examination. The company lowered its fiscal 2026 guidance to non-GAAP EPS of $4.51 to $4.55.

Last earnings

September 9, 2026 (8-K on sec.gov)

Next earnings

December 3, 2026, as the company confirmed.

• 8-KChange of directors or officers and Investor disclosureFiled October 27, 2026 · Read it on sec.gov
• 10-QQuarterly report for the period ended Jul 31, 2026Filed September 9, 2026 · coo-20260731
• 8-KEarnings release and Other company newsFiled September 9, 2026 · Press release and exhibits
• 10-QQuarterly report for the period ended Apr 30, 2026Filed June 5, 2026 · coo-20260430
• 8-KEarnings release and Other company newsFiled June 4, 2026 · Press release and exhibits
• 8-KChange of directors or officersFiled May 4, 2026 · coo-20260504
• 8-KShareholder vote resultsFiled April 8, 2026 · coo-20260407
• 10-QQuarterly report for the period ended Jan 31, 2026Filed March 6, 2026 · coo-20260131
• 8-KEarnings releaseFiled March 5, 2026 · Press release and exhibits
• 8-KNew material agreementFiled February 4, 2026 · Read it on sec.gov

Every filing on SEC EDGAR (CIK 711404)

• CooperVision revenue was flat in Q3 fiscal 2026, and the company expects Q4 organic growth of minus 2% to 0%. If growth does not return after the inventory reduction, earnings and the share price can stay low.
• The company has no permanent CEO since October 27, 2026. A long search or a new leader who changes the strategy can delay the plans for growth and buybacks.
• The board said that a new competitor is entering the non-hormonal IUD market, where CooperSurgical competes. More competition can lower CooperSurgical revenue.
• A U.K. tribunal decided in March 2026 that the company did not withhold enough payroll taxes on part of the price for the Sauflon acquisition. The company is appealing and estimates a possible loss of 0 to 71.7 million pounds plus interest.
• Debt rose to $2.54 billion at July 31, 2026, as the company bought back shares. More buybacks with borrowed money increase leverage.

CooperCompanies funds itself with bank debt. At July 31, 2026, total debt was $2.54 billion: $966.7 million drawn on the $2.3 billion revolving credit facility that matures on May 1, 2029, term loans of $1.50 billion, of which $550 million is due within a year, and other debt. Read more

The Cooper Companies does not pay a dividend.

Source: company filings and market data, read on November 13, 2026.